On the List of 2013 Top 100 Companies in China Pharmaceutical Industry jointly released by CFDA Southern Medicine Economic Research Institute (SMERI) and Medicine Economic News on May 26th, Fosun Pharma’s Pharmaceutical Business ranked 14th from last year’s 17th place. Established in 2006, so far this Top 100 List has been issued for 8 consecutive years, and for 4 consecutive years Fosun Pharma’s Pharmaceutical Business has constantly polished its rankings year by year.

As the core business, Fosun Pharma’s Pharmaceutical Business maintained a good growth in 2013. After years of mergers and acquisitions, R&D and marketing, Fosun Pharma has developed market-leading products in all its five segmental therapeutic areas, meanwhile maintaining rapidly grown sales of its core products. Currently 15 products have achieved sales of over RMB100 million respectively. In the future, Fosun Pharma will further take advantage of its resources to develop core pharmaceutical business, and enhance the competitiveness of the company.

As an annual event jointly organized by CFDA SMERI and Medicine Economic News, the List of Top 100 Companies in China Pharmaceutical Industry is influential in the pharmaceutical industry thanks to its professionalism, exclusivity and authenticity. For the 2013 event, the rankings were given based on intensive investigation to those pharmaceutical companies registered in China (excluding multinational pharmaceutical companies’ subsidiaries in China) whose main business is pharmaceutical manufacturing, demonstrating an objective, in-depth landscape of Chinese leading pharmaceutical companies.